The final results of the study confirming the effectiveness of CIMAvax-EGF in advanced lung cancer will be presented at an international workshop to be held in Havana on May 12-13.
The implementation of the vaccine-conceived by experts of the Center for Molecular Immunology (CIM)- in primary health care, its overall safety profile and post-registration experiences in other countries, will also be discussed at the V International Workshop on the subject, to be held at Havana’s Conference Center.
The event, organized by CIMAB S.A. -a Cuban biopharmaceutical company dedicated to the development and commercialization of drugs for the treatment of malignant tumors- will aim at discussing new indications and therapeutic combinations of the compound.
CIMAvax-EGF is the first registered therapeutic vaccine for lung cancer and is considered a new strategy, capable of generating the patient’s own antibodies against the epidermal growth factor (EGF).
Antibodies generated stop the proliferation of tumor cells and consequently the disease progression is controlled, survival increases as well as the quality of life of treated patients.
Results of Cuban Lung-Cancer Vaccine to Be Presented in Cuba
Havana, May 9 The final results of the study confirming the effectiveness of CIMAvax-EGF in advanced lung cancer will be presented at an international workshop to be held in Havana on May 12-13.
The implementation of the vaccine-conceived by experts of the Center for Molecular Immunology (CIM)- in primary health care, its overall safety profile and post-registration experiences in other countries, will also be discussed at the V International Workshop on the subject, to be held at Havana’s Conference Center.
The event, organized by CIMAB S.A. -a Cuban biopharmaceutical company dedicated to the development and commercialization of drugs for the treatment of malignant tumors- will aim at discussing new indications and therapeutic combinations of the compound.
CIMAvax-EGF is the first registered therapeutic vaccine for lung cancer and is considered a new strategy, capable of generating the patient’s own antibodies against the epidermal growth factor (EGF).
Antibodies generated stop the proliferation of tumor cells and consequently the disease progression is controlled, survival increases as well as the quality of life of treated patients.
(Prensa Latina)